5-(Trifluoromethyl)benzo[b]furan-2-carbaldehyde | 496949-41-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 5-(Trifluoromethyl)benzo[b]furan-2-carbaldehyde
• 英文别名: 5-trifluoromethyl-benzofuran-2-carbaldehyde；5-trifluoromethylbenzofuran-2-carbaldehyde；5-(Trifluoromethyl)-1-benzofuran-2-carbaldehyde
• CAS: 496949-41-8
• 化学式: C₁₀H₅F₃O₂
• 分子量: 214.144
• InChiKey: OHYIYUFJOCTHQO-UHFFFAOYSA-N

物化性质

• 沸点：
  259.0±35.0 °C(Predicted)
• 密度：
  1.413±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  30.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(Trifluoromethyl)benzo[b]furan-2-carbaldehyde 、 对甲基苯磺酰甲基异腈 在 sodium cyanide 氨 作用下， 以 乙醇 、 甲醇 为溶剂， 反应 14.67h， 生成 4-(5-trifluoromethyl-benzofuran-2-yl)-imidazole
  参考文献：
  名称：

  [EN] IMIDAZOLYL PYRIMIDINE DERIVATIVES USEFUL AS IL-8 RECEPTOR MODULATORS
  [FR] DERIVES DE D'IMIDAZOLYL PYRIMIDINE UTILISES COMME MODULATEURS DU RECEPTEUR DE IL-8

  摘要：

  该发明涉及公式I的化合物，其中R1、R2、R3和R4分别独立地选择自H、(1-4C)烷基、(1-4C)烷氧基、三氟甲基、三氟甲氧基、卤素、氨基、磺酰胺基、氰基、羟基和硝基；R5为H或(1-6C)烷基；R6为H、(1-6C)烷基或(1-6C)烷氧基；R7为H或(1-6C)烷基；R8为(1-6C)烷基，可选地取代为(1-6C)烷氧基；R9为-(CH2)nR10，其中n为1、2或3，R10选自(1-4C)烷氧基、(1-4C)烷基硫醚、三氟甲基、(3-8C)环烷基、苯基，可选地取代为(1-4C)烷氧基，-NR11R12和-O(CH2)2NR11R12，其中R11和R12中的一个为(1-4C)烷氧基，另一个为H或(1-4C)烷基，或R9为-CH2(2-7C)杂环烷基，但至少一个杂原子在杂环烷基基团中是氮时，该氮与“NHR9”中的氮之间的距离至少为三个碳原子，或R9为-(CH2)3(2-7C)杂环烷基或-(CH2)2CHR13R14，其中R13和R14与它们连接的碳原子一起，是(2-7C)杂环烷基；X为O、S或NH；或其药学上可接受的盐。该发明的化合物是Il-8受体调节剂，特别是其抑制剂，并可用于治疗或预防Il-8受体介导的疾病，如动脉粥样硬化、炎症、类风湿关节炎及相关疾病。

  公开号：

  WO2004063192A1
• 作为产物：
  描述：

  1-benzofuran-2-ol 在 pyridinium chlorochromate 作用下， 以 二氯甲烷 、 乙酸乙酯 为溶剂， 以9.2 g (80%)的产率得到5-(Trifluoromethyl)benzo[b]furan-2-carbaldehyde
  参考文献：
  名称：

  Pharmaceutical compounds and methods of use thereof

  摘要：

  本发明提供了取代苯并呋喃、茚、硫代萘和氧化硫代萘化合物，以及包含这些化合物的治疗方法和药物组合物。本发明的优选化合物包含取代有四氢呋喃或其他脂环基团的苯并呋喃、茚或硫代萘基团。

  公开号：

  US20030055084A1

文献信息

• [EN] (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIC ACID AMINOETHYLAMID DERIVATIVES AS IL-8 RECEPTOR MODULATORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS<br/>[FR] DERIVES D'AMINOETHYLAMIDE D'ACIDE (2S)-2-((PYRIMIDIN-4-YL)AMINO)-4-METHYLPENTANOIQUE UTILISES COMME MODULATEURS DU RECEPTEUR DE L'IL-8 POUR TRAITER L'ATHEROSCLEROSE ET LA POLYARTHRITE RHUMATOIDE
  申请人：PHARMACOPEIA DRUG DISCOVERY

  公开号：WO2004069829A1

  公开（公告）日：2004-08-19

  The invention relates to compounds of the formula: (I); wherein R1 is a basic moiety having the structure -NH(CH2)2NR5R6, (Formula II) or (Formula II); wherein R5, R6 and R7 are independently selected from H, (1-6C)alkyl, (2-6C)alkenyl; (3-8C)cycloalkyl, and (1-6C)alkyl substituted with furanyl, (1-6C)alkoxy, (3-8C)cycloalkyl, trifluoromethyl or amido; or R5 and R6 together with N to which they are attached are a (4-8) membered heterocycle, which heterocycle may be substituted with (1-6C)alkoxy, trifluoromethyl or amido and which heterocycle may be fused with another (5-6) membered heterocycle; n is 1, 2 or 3; and the ring structure A represents a (4-6) membered heterocycle; R2 is (1-6C)alkyl, optionally substituted with (1-6C)alkoxy; R3 is aryl, heterocyclyl, -X-(CH2)maryl or -X-(CH2)m-heterocyclyl, wherein X is O, S or NR8, R8 being H or (1-6C)alkyl, and m is 0, 1, 2 or 3; and R4 is H, (1-8C)akyl, (1-8C)alkoxy or (2-8C)alkenyl, the alkyl moiety of each optionally being substituted with hydroxy, halogen, cyano, nitro, oxo, amino, alkylamino, dialkylamino, amido, alkylamido, carboxy, (1-8C)alkoxy, (1-8C)alkylthio, perfluoro (1-4C)alkyl, (3-8C)cycloalky, aryl, aryloxy, heterocyclyl or-0-heterocyclyl; or a pharmaceutically acceptable salt thereof. The compounds of the invention are Il-8 receptor modulators, in particular inhibitors thereof, and can be used for treating or preventing Il-8 receptor mediated disorders, such as atherosclerosis, inflammation, rheumatoid arthritis and related disorders.

  该发明涉及以下式的化合物：（I）；其中R1是具有结构-NH(CH2)2NR5R6的碱性基团，（式II）或（式II）；其中R5、R6和R7分别选自H、（1-6C）烷基、（2-6C）烯基；（3-8C）环烷基，以及用呋喃基、（1-6C）烷氧基、（3-8C）环烷基、三氟甲基或酰胺取代的（1-6C）烷基；或者R5和R6与它们连接的N一起是（4-8）成员杂环，该杂环可以用（1-6C）烷氧基、三氟甲基或酰胺取代，并且该杂环可以与另一个（5-6）成员杂环融合；n为1、2或3；环结构A代表（4-6）成员杂环；R2是（1-6C）烷基，可选地取代（1-6C）烷氧基；R3是芳基、杂环基、-X-(CH2)芳基或-X-(CH2)m-杂环基，其中X为O、S或NR8，R8为H或（1-6C）烷基，m为0、1、2或3；R4为H、（1-8C）烷基、（1-8C）烷氧基或（2-8C）烯基，每个烷基基团可选地取代羟基、卤素、氰基、硝基、氧代、氨基、烷基氨基、二烷基氨基、酰胺、烷基酰胺、羧基、（1-8C）烷氧基、（1-8C）烷基硫氧基、全氟（1-4C）烷基、（3-8C）环烷基、芳基、芳氧基、杂环基或-0-杂环基；或其药学上可接受的盐。该发明的化合物是Il-8受体调节剂，特别是其抑制剂，并可用于治疗或预防Il-8受体介导的疾病，如动脉粥样硬化、炎症、类风湿关节炎及相关疾病。
• VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL INHIBITOR
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：EP3404021A1

  公开（公告）日：2018-11-21

  A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2, provide that n and m are not 0 and 2 at the same time.

  由以下通式（I）代表的化合物、该化合物的同系物或立体异构体、其药学上可接受的盐或其溶液可用作电压依赖性 T 型钙通道阻滞剂： 其中 A 代表可具有取代基的融合环，该融合环由 5 元杂芳基或 5 元或 6 元杂环和苯环或类似物组成，5 元杂芳基具有 1 至 3 个相同或不同的杂原子作为成环元素，具有至少一个取代基，例如具有 1 至 8 个碳原子并被 1 至 5 个卤素原子取代的烷氧基；R 代表氢原子或类似物；B 代表 CR5(Q1) 或 NQ2，其中 Q1 代表可能具有取代基的苯并咪唑基；Q2 代表可能具有取代基的具有 1 至 8 个碳原子的烷基、可能具有取代基的杂芳基或类似物；R0、R1、R2、R3、R4 和 R5 各代表氢原子或类似物；n 和 m 各代表 0、1 或 2，但 n 和 m 不能同时为 0 和 2。
• VOLTAGE-DEPENDENT T-TYPE CALCIUM CHANNEL BLOCKER
  申请人：Nippon Chemiphar Co., Ltd.

  公开号：US20190077767A1

  公开（公告）日：2019-03-14

  A compound represented by the following General Formula (I), a tautomer or a stereoisomer of the compound, a pharmaceutically acceptable salt thereof, or a solvate thereof, is used as a voltage-dependent T-type calcium channel blocker: wherein A represents a fused ring which may have a substituent, the fused ring being composed of a 5-membered heteroaryl group or a 5-membered or 6-membered heterocyclic ring and a benzene ring or the like, the 5-membered heteroaryl group having one to three identical or different heteroatoms as a ring-constituting element(s) having at least one substituent such as an alkoxy group having 1 to 8 carbon atoms and substituted with 1 to 5 halogen atoms; R represents a hydrogen atom or the like; B represents CR5(Q1) or NQ2, herein Q1 represents a benzimidazole group which may have a substituent; Q2 represents an alkyl group having 1 to 8 carbon atoms which may have a substituent, a heteroaryl group which may have a substituent, or the like; R0, R1, R2, R3, R4, and R5 each represent a hydrogen atom or the like; and n and m each represent 0, 1, or 2, provide that n and m are not 0 and 2 at the same time.
• [EN] BENZOHETEROCYCLES AS LIPOXYGENASE INHITIBORS<br/>[FR] BENZOHETEROCYCLES UTILISES COMME INHIBITEURS DE LIPOXYGENASE
  申请人：MILLENNIUM PHARM INC

  公开号：WO2003011848A1

  公开（公告）日：2003-02-13

  The present invention provides substituted benzofuran, indene, thianaphthene and oxidized thianaphthene compounds and methods of treatment and pharmaceutical compositions that comprise such compounds. Preferred compounds of the invention contain benzofuran, indene or thianaphthene group substituted with a tetrahydrofuran or other alicyclic group.
• Pharmaceutical compounds and methods of use thereof
  申请人：Millennium Pharmaceutical, Inc.

  公开号：US20030055084A1

  公开（公告）日：2003-03-20

  The present invention provides substituted benzofuran, indene, thianaphthene and oxidized thianaphthene compounds and methods of treatment and pharmaceutical compositions that comprise such compounds. Preferred compounds of the invention contain benzofuran, indene or thianaphthene group substituted with a tetrahydrofuran or other alicyclic group.

  本发明提供了取代苯并呋喃、茚、硫代萘和氧化硫代萘化合物，以及包含这些化合物的治疗方法和药物组合物。本发明的优选化合物包含取代有四氢呋喃或其他脂环基团的苯并呋喃、茚或硫代萘基团。